Cost–Utility Analysis of Palonosetron-Based Therapy in Preventing Emesis Among Breast Cancer Patients

This study was supported in part by a grant from MGI Pharma, Inc. MGI Pharma, Inc., had no role in the study design, data analysis, interpretation of results, content of the final article, or the decision to submit it for publication.

Conflicts of interest: Dr. Sun discloses that her husband was an employee of MGI Pharma, Inc., at the time this article was being written. Dr. Gralla discloses that he is a consultant for MGI Pharma, Inc., GlaxoSmithKline, Sanofi-aventis, and Merck; he also receives honoraria from MGI Pharma, Inc., and Merck and research support from Sanofi-aventis. Dr. Grunberg discloses that he is a consultant for MGI Pharma, Inc.

Correspondence to: Elenir B. C. Avritscher, MD, PhD, MBA/MHA, Section of Health Services Research, Department of Biostatistics and Applied Mathematics, The University of Texas M. D. Anderson Cancer Center, 1400 Pressler Street, Unit 1411, Houston, TX 77230; telephone: (713) 563-8920; fax: (713) 563-4243

¹ PubMed ID in brackets